Intuitive Surgical: Insider Selling, a Legal Setback, and the Weight-Loss Drug Question
Published on 08/23/2026 at 03:02 | Redaktion boerse-global.de
The da Vinci surgical robot remains a formidable profit engine, but Intuitive Surgical's share price tells a more complicated story. Trading at €324.65 after Friday's close — a 1.3% gain on the day — the stock sits roughly 37% below its 52-week high of €516.50 and well under its 200-day moving average of $406.17. With the shares down 34% since the start of the year, investors are weighing a cluster of cross-currents: a dense stretch of insider selling, an appellate court ruling that chips away at the company's aftermarket dominance, and the creeping influence of GLP-1 weight-loss drugs on surgical volumes.
A Concentrated Wave of Insider Sales
Between August 10 and August 21, no fewer than five senior figures at Intuitive Surgical reduced their positions. The most conspicuous transaction came from director Gary Guthart, who sold 10,000 shares on August 11 for a total of $4 million. That same day, chief legal and compliance officer Gary Loeb and director Amy Ladd each offloaded 400 shares at $379.
Chief manufacturing and supply chain officer Mark Brosius was the most active seller, executing trades across four consecutive sessions — 77 shares per day at prices ranging from $375.57 to $396.37. A subsequent pair of transactions brought his total disposals to 154 shares, leaving him with a direct holding of 881 shares.
To be fair, nearly all of these trades ran through pre-arranged Rule 10b5-1 plans, which are designed to shield executives from insider-trading accusations by automating sales on a fixed schedule. That mechanical detail matters: these were not spontaneous decisions triggered by fresh information. Still, the sheer density of sellers within a two-week window — and the fact that no insider appears to have been buying — suggests management is comfortable taking chips off the table at current levels.
Institutional money has told a somewhat different story. Plato Investment Management, for instance, built a new position worth over $4.3 million during the second quarter. That provides some counterweight, though it does little to change the picture of insider behavior.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
The Ninth Circuit Opens a Door
The selling wave coincided with a legal development that could have longer-term implications. On August 17, the U.S. Court of Appeals for the Ninth Circuit overturned a ruling that had favored Intuitive Surgical in its antitrust dispute with Surgical Instrument Service Co. (SIS), a competitor in the market for refurbished instruments.
The appellate panel determined that SIS should not be held to the traditional "Kodak/Epic" standard to establish a standalone aftermarket for reprocessed instruments. The reasoning hinges on Intuitive's near-100% market power in the primary market for surgical robots — a dominance that, in the court's view, changes how the aftermarket should be analyzed.
This is potentially significant for a business model built heavily on controlling the ecosystem of instruments and replacement parts that surgeons use with the da Vinci system. The ruling does not resolve the underlying litigation, but it does crack the door for future challenges from aftermarket competitors. For a company whose razor-and-blades economics depend on that control, the legal risk just got a little harder to dismiss.
Analysts Split, and a New Demand-Side Worry Emerges
Wall Street's response to the recent pullback has been anything but uniform. Piper Sandler reaffirmed its "Overweight" rating with a $470 price target on August 21, explicitly calling the recent decline "not justified." UBS also maintains a "Buy" rating with a $500 target, and Bernstein keeps an "Outperform" — though it trimmed its price objective from $750 to $685, citing concerns about U.S. growth momentum.
On the other side, Wall Street Zen downgraded the stock from "Buy" to "Hold" on August 15. The divergence underscores just how uncertain professional observers are about the near-term trajectory.
Adding to the mix is a structural question that has been quietly reshaping the demand outlook: the rise of GLP-1 weight-loss medications. Reports indicate that growth in bariatric surgery — the very procedures Intuitive's robots often assist with — is slowing noticeably in the U.S. as patients increasingly opt for pharmaceutical alternatives. That dynamic is being closely monitored, given the company's leading position in minimally invasive surgery.
The Fundamentals Still Point Up
For all the near-term noise, the underlying business continues to perform. Second-quarter results, reported roughly a month ago, showed revenue climbing 19% to $2.89 billion, with adjusted earnings per share up 28% to $2.80. Management responded by raising its non-GAAP gross margin guidance for fiscal 2026.
Longer-term bulls are also looking past the current turbulence toward the ongoing digitalization of operating rooms and the rollout of next-generation systems like the da Vinci 5. The question is whether the stock's valuation — still rich by most historical measures — leaves room for disappointment on any of the three fronts now weighing on sentiment: insider behavior, litigation exposure, or the medication-driven shift in surgical demand. For now, the risk-reward calculus remains genuinely mixed, and the market seems to know it.
Ad
Intuitive Surgical Stock: New Analysis - 23 August
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
